Beacon HJ and Thompson SG. Multilevel models for repeated measurement data: Application to quality-of-life data in clinical trials. Statistics in Medicine, 1996;16;2717-2732.

Beacon HJ, Thompson SG and England PD. The analysis of complex patterns of binary response: An example of transient dysphagia following radiotherapy. Statistics in Medicine, 1998;17;2551-2561.

Frost C, Clarke R and Beacon HJ. Using multilevel models to perform meta-analysis of partial regression coefficients illustrated with an overview of dietary determinants of serum cholesterol levels. Statistics in Medicine, 1999;18;1657-1676.

Ribaudo HJ, Bacchi M, Bernhard J and Thompson SG. Evaluation of the level of physical performance of women receiving adjuvant therapy for the treatment of breast cancer: an analysis of longitudinal ordinal data. Journal of the Royal Statistical Society, Series A, 1999;162;349-360.

HIV Surrogate Marker Collaborative Group [HJ Ribaudo was one of three members of the Coordinating Center who took responsibility for this manuscript]. Human Immunodeficiency Virus Type 1 (HIV-1) RNA Level and CD4 Count as Prognostic Markers and Surrogate Endpoints: A Meta-Analysis. AIDS Research and Human Retroviruses, 2000;10;1123-33.

Gilbert P, Ribaudo HJ, Greenberg L, Yu G., Bosch RJ, Tierney, C and Kuritzkes DR. Considerations in choosing a primary virological endpoint for durability in AIDS antiretroviral trials. AIDS, 2000;14;1961-1972.

Ribaudo HJ, Thompson SG and Allen-Mersh TG. A Joint Analysis of Quality of Life and Survival using a Random Effect Selection Model. Statistics in Medicine, 2000;19;3237-3250.

Ribaudo HJ, Thompson SG. The analysis of repeated multivariate binary quality of life data: a hierarchical model approach. Statistical Methods in Medical Research, 2002;11;69-83.

Fischl MA, Ribaudo HJ, Collier AC, Erice A, Giuliano M, Dehlinger M, Eron J, Saag M, Hammer S, Vella S, Morse GD and Feinberg J, A randomized trial comparing two different four-drug antiretroviral regimens with a three-drug regimen in persons with advanced HIV disease. Journal of Infectious Diseases, 2003;188(5);625-34.

Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S,Squires KE, Meyer WA, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR Triple nucleoside analogue vs. efavirenz-containing regimens for the initial treatment of HIV-1 infection: AIDS Clinical Trials Group (ACTG) Study A5095. New England Journal of Medicine, 2004;350(18): 1850-1861.

Demeter LM, Ribaudo HJ, Erice A, Eshleman SH, Hammer SM, Hellmann NS, and Fischl MA. HIV-1 Drug Resistance in Subjects with Advanced HIV-1 Infection Failing Antiretroviral Combination Therapy – A Substudy of AIDS Clinical Trials Group (ACTG) Study Protocol 388. Clinical Infectious Diseases, 2004;39(4):552-8.

Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Clifford D, Gulick RM, Hulgan T, and Acosta EP. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group Study. AIDS, 2004;18:2391-2400.

Collier AC, Ribaudo H, Feinberg J, Mukherjee L, Fischl M, and Chesney M for the ACTG Protocol 746 Team. Randomized Study of Telephone Calls to Improve Adherence to Antiretroviral Therapy, Journal of Infectious Diseases, 2005;192(8):1398-406.

Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, Gulick RM, Clifford DB, Marzolini C, Fletcher CV, Tashima KT, Kuritzkes DR, Acosta EP. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis., 2006;42(3):401-7.

Gulick RM, Ribaudo HJ, Shikuma CM, Lalama CL, Schackman BR, Meyer WA, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR. Randomized, Double-Blinded, Multicenter Study of a Three- vs. Four-Drug Antiretroviral Regimen for the Initial Treatment of HIV-1 Infection, JAMA, 2006;296(7):769-81.

Gripshover B, Ribaudo HJ, Santana J, Gerber J, Campbell T, Hogg E, Jarocki B, Hammer S, and Kuritzkes DR. A Randomized, Placebo-controlled Trial of Amdoxovir vs Placebo with Enfuvirtide plus Optimized Background Therapy for HIV-infected Subjects Failing Current Therapy (AACTG 5118). Antiviral Therapy. 2006;11(5):619-23.

Ribaudo HJ, Kuritzkes DR, Schackman BR, Acosta EP, Shikuma CM, and Gulick RM. Design issues in initial HIV-treatment trials  focus on ACTG A5095, Antiviral Therapy. 2006; 11: 751-760.

Gulick RM, Lalama C, Ribaudo HJ, Shikuma CM, Schackman BR, Schouten J, Squires KE, Acosta EP, Meyer WA, Koletar SL, Pilcher CD, Reichman RC, Santana JL, Hughes V, Bastow B, Klingman KL, Kuritzkes DR. Intensification of a Triple-Nucleoside Regimen With Tenofovir or Efavirenz in HIV-Infected Subjects With Virologic Suppression (Aids Clinical Trials Group Study A5095): A Randomized, Comparative Study, AIDS. To appear.

Kuritzkes DR, Ribaudo HJ, Squires KE, Koletar S, Santana J, et al. Relationship of plasma HIV-1 RNA dynamics to treatment regimen and sex in antiretroviral-na